Pirfenidone

吡非尼酮

Report date: 2026/04/23 20:00:25
NMEFirst In Class

Base Information

Drug NamePirfenidone
Drug Alias Name哌非尼酮pirfenidona吡啡尼酮pirfenidonum甲苯吡啶酮 +[17] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionTransforming growth factor beta inhibitorsCytokines inhibitorsCollagen inhibitors
TargetsTransforming growth factor betaCytokinesCollagen
Therapy Area/IndicationsRejection of lung transplantationCoronavirus Disease 2019 (COVID-19)systemic sclerosis-associated interstitial lung disease +[42] 
Global Approved IndicationsIdiopathic Pulmonary Fibrosis
Approved Indications in ChinaIdiopathic Pulmonary Fibrosis
Original Approved Country/TerritoryJapan
Original Approved Date2008/10/16
Country/TerritoryCzechiaBelgiumCanada +[23] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesIntermune Inc
China Registration ClassN/A

Develop Information

Active CompaniesUniversity Of California San FranciscoLegacy Pharma USA IncStanford University +[13] 
Inactive CompaniesInstituto Nacional De Ciencias Medicas Y Nutricion Salvador ZubiranInstituto De Investigación E Innovación Biomédica De CádizOverseas Pharmaceuticals Ltd +[22] 
Active IndicationsRejection of lung transplantationCoronavirus Disease 2019 (COVID-19)Graft vs Host Disease +[16] 
Inactive Indicationssystemic sclerosis-associated interstitial lung diseaseFibrosisDiabetes Mellitus +[26] 

Other Information

ATC CodeL04AX05
Related LinksWikipediaDrugBankKEGG